American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Updated phase 1b results of SYMPHONY-1 with 22.5 months follow-up
    Meeting Abstract

    Salles, G.; Park, S. I.; Phillips, T. J.; Amengual, J. E.; Andorsky, D. J.; Campbell, P.; McKay, P.; Leonard, J. P.; Chen, Y. X.; Chen, J. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study
    Meeting Abstract

    Morschhauser, F.; Leung, W.; Raghavan, V.; Lenz, G.; Jardin, F.; Herrera, A. F.; Sehn, L. H.; Sharman, J. P.; Flowers, C. R.; Friedberg, J. W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CD33-TIM3 dual CAR T cells: Enhancing specificity while maintaining efficacy against AML
    Meeting Abstract

    Wang, Y.; Lu, W.; Rohrbacher, L.; Flaswinkel, H.; Emhardt, A. J.; Magno, G.; Haubner, S.; Kobold, S.; Leonhardt, H.; Hopfner, K. P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Strategies to develop anti-KIR mab lacutamab in patients with peripheral T-cell lymphoma: Preliminary monotherapy clinical data and pre-clinical combinability data
    Meeting Abstract

    Iyer, S. P.; Ayyappan, S. R.; Greenwell, I. B.; Kim, W. S.; Lee, S. T.; Kim, J. S.; Lee, W. S.; Jeon, Y.; Johnson, W.; Dave, U. P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical factors associated with cytokine release syndrome and dosing recommendations for restarting elranatamab following an interruption
    Meeting Abstract

    Niesvizky, R.; Arnulf, B.; Mohty, M.; Nooka, A. K.; Manier, S.; Tomasson, M.; Bahlis, N. J.; Irby, D.; Hibma, J.; Viqueira, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating inpatient care team models in hematology and oncology fellowship programs in the United States
    Meeting Abstract

    Stempel, J. M.; Li, A. J.; Pine, A. B.; Restrepo, V.; Bewersdorf, J. P.; Stahl, M.; Podoltsev, N. A.; Mendez, L.; Shallis, R. M.; Rangachari, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of DFV890 in adult patients with myeloid diseases: A phase 1b study
    Meeting Abstract

    Garcia-Manero, G.; Ooi, M.; Lao, Z. T.; Gill, H.; Abaza, Y.; Stahl, M.; Haque, T.; DeZern, A. E.; Greenberg, P. L.; Pelletier, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Primary endpoint analysis from a response adaptive phase II clinical trial of carfilzomib, lenalidomide, dexamethasone plus daratumumab (KRd-Dara) in patients with newly diagnosed multiple myeloma (NDMM)
    Meeting Abstract

    Bhutani, M.; Robinson, M.; Atrash, S.; Paul, B.; Pineda-Roman, M.; Foureau, D.; Varga, C.; Friend, R.; Begic, X.; Norek, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1 study of avapritinib in combination with decitabine in patients with systemic mastocytosis with an associated hematologic neoplasm
    Meeting Abstract

    Kuykendall, A. T.; Ball, S.; Gotlib, J.; Yi, C. Y. A.; Tashi, T.; Rampal, R. K.; DeAngelo, D. J.; Volpe, V. O.; Pettit, K. M.; Komrokji, R. S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Trial in progress: An open-label expansion trial evaluating the safety, PK/PD, and clinical activity of emavusertib (CA-4948) + ibrutinib in R/R primary CNS lymphoma
    Meeting Abstract

    Grommes, C.; Nowakowski, G. S.; Rosenthal, A. C.; Lunning, M. A.; Ramchandren, R.; Regales, L.; Fowle, M.; Lane, M.; Wang, C.; Omuro, A.; more...
    Blood (2023)

    Fulltext@MSK | Save